Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2013

Quarterly Financial Information Disclosure [Abstract]

Quarterly Financial Data (Unaudited)

Quarterly Financial Data (Unaudited)

(In millions, except per share amounts)	First Quarter		Second Quarter		Third Quarter		Fourth Quarter		Total Year
2013	(a)		(b)		(b) (c)		(b)
Product revenues	$	1,095.8	$	1,385.9	$	1,453.6	$	1,607.1	$	5,542.3
Unconsolidated joint business revenues	$	264.6	$	288.8	$	303.2	$	269.4	$	1,126.0
Other revenues	$	54.7	$	48.8	$	71.0	$	89.4	$	263.9
Total revenues	$	1,415.1	$	1,723.5	$	1,827.8	$	1,965.9	$	6,932.2
Gross profit	$	1,281.4	$	1,492.8	$	1,593.1	$	1,707.3	$	6,074.5
Net income	$	426.7	$	490.7	$	487.6	$	457.3	$	1,862.3
Net income attributable to Biogen Idec Inc.	$	426.7	$	490.7	$	487.6	$	457.3	$	1,862.3
Basic earnings per share attributable to Biogen Idec Inc.	$	1.80	$	2.07	$	2.06	$	1.94	$	7.86
Diluted earnings per share attributable to Biogen Idec Inc.	$	1.79	$	2.06	$	2.05	$	1.92	$	7.81

(In millions, except per share amounts)	First Quarter		Second Quarter		Third Quarter		Fourth Quarter		Total Year
2012	(d)						(e) (f)
Product revenues	$	975.4	$	1,076.8	$	1,039.1	$	1,074.7	$	4,166.1
Unconsolidated joint business revenues	$	284.6	$	284.6	$	287.8	$	280.9	$	1,137.9
Other revenues	$	32.0	$	59.6	$	58.6	$	62.3	$	212.5
Total revenues	$	1,292.0	$	1,421.0	$	1,385.5	$	1,417.9	$	5,516.5
Gross profit	$	1,158.8	$	1,281.8	$	1,246.2	$	1,284.1	$	4,971.0
Net income	$	302.4	$	387.1	$	398.4	$	292.1	$	1,380.0
Net income attributable to Biogen Idec Inc.	$	302.7	$	386.8	$	398.4	$	292.1	$	1,380.0
Basic earnings per share attributable to Biogen Idec Inc.	$	1.26	$	1.62	$	1.68	$	1.24	$	5.80
Diluted earnings per share attributable to Biogen Idec Inc.	$	1.25	$	1.61	$	1.67	$	1.23	$	5.76

Full year amounts may not sum due to rounding.

(a) Our share of revenues from unconsolidated joint business reflects a charge of $41.5 million for damages and interest awarded to Hoechst in Genentech's arbitration with Hoechst for RITUXAN.

(b) Product revenues and total revenues for the second, third and fourth quarters of 2013 includes 100% of net revenues related to sales of TYSABRI as a result of our acquisition of TYSABRI rights from Elan on April 2, 2013 and net revenues related to sales of TECFIDERA, our new oral first-line treatment for people with relapsing forms of multiple sclerosis (MS), which was approved by the FDA in March 2013 and commenced commercial sales in April 2013.

(c) Net income and net income attributable to Biogen Idec Inc., for the third quarter of 2013, includes a charge to research and development expense of $75.0 million related to an upfront payment made in connection with our collaboration agreement entered into with Isis.

(d) Net income and net income attributable to Biogen Idec Inc. for the first quarter of 2012 includes a charge to research and development expense of $29.0 million related to an upfront payment made in connection with our development agreement entered into with Isis.

(e) Net income and net income attributable to Biogen Idec Inc. for the fourth quarter of 2012 includes the correction of an error that had accumulated over several prior years in our deferred tax accounting for capitalized interest which resulted in an expense of $29.0 million.

(f) Net income and net income attributable to Biogen Idec Inc. for the fourth quarter of 2012 includes a charge to research and development expense of $30.0 million related to an upfront payment made in connection with our development agreement entered into with Isis.